AnaptysBio to Present Data from ANB020 Program at Two

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
40
AnaptysBio to Present Data from ANB020 Program at Two Upcoming Medical Meetings

SAN DIEGO, Feb. 13, 2017 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB ), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that the company will present data from its ANB020 program, its wholly-owned anti-IL-33 antibody, at the 2017 American Academy of Dermatology (AAD) Annual Meeting and the American Academy of Allergy, Asthma and Immunology (AAAAI) 2017 Annual Meeting. The AAD Annual Meeting is being held March 3-7, 2017 at the Orange County Convention Center in Orlando, Fla., and the AAAAI Annual Meeting is being held March 3-6, 2017 at the Georgia World Congress Center in Atlanta.

Details of the presentations are as follows:  

AAD Annual Meeting Oral Presentation Date: Friday, March 3, 2017 Time: 2:55 – 3:00 p.m. ET Abstract Title: 5039. A Phase 1 Study of ANB020, an Anti-IL-33 Monoclonal Antibody, in Healthy Volunteers Location: e-Poster Presentation Center 3

AAAAI Annual Meeting Poster Presentation Date: Saturday, March 4, 2017 Time: 9:45 -10:45 a.m. ET Abstract Title: 30949. A Phase 1 Study of ANB020, an Anti-IL-33 Monoclonal Antibody, in Healthy Volunteers Poster Number: 232 Session Number: 2213 Session Title: Innate Lymphoid Cells, T-Cells and Dendritic Cells Location: Georgia World Congress Center, Level One, South Exhibit Hall B2

About ANB020 ANB020 is a potentially first-in-class antibody that inhibits the activity of IL-33, a pro-inflammatory cytokine that multiple studies have indicated is a central mediator of atopic diseases, including atopic dermatitis, food allergies and asthma. IL-33 directly mediates the release of disease-associated cytokines, which recruit pro-inflammatory cells that mediate atopic disease. Because ANB020 inhibits IL-33 function and acts upstream broadly across the key cell types and cytokines involved in atopy, we believe that its mechanism has advantages in the treatment of atopic diseases over competing agents that block only a subset of the cytokines responsible for atopic diseases. The role of IL-33 signaling in asthma has recently been genetically validated through human studies published in the medical literature. We have cleared a U.S. IND and a U.K. CTA to initiate Phase 2a trials of ANB020 for the treatment of severe adult peanut allergy and moderate-to-severe adult atopic dermatitis, respectively, where we anticipate top-line data from these trials to be announced during the second half of 2017. In addition, we plan to seek regulatory clearance during the first half of 2017 to initiate a Phase 2a trial in patients with severe adult eosinophilic asthma, where we anticipate top-line data from this trial to be announced during the first half of 2018.

About AnaptysBio AnaptysBio is a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes its anti-IL-33 antibody (ANB020) for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy and severe adult eosinophilic asthma; its anti-IL-36R antibody (ANB019) for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases where immune checkpoint receptors are insufficiently activated and have demonstrated efficacy in an animal model of graft-versus-host disease. AnaptysBio's antibody pipeline has been developed using its proprietary SHM platform, which uses in vitro somatic hypermutation for antibody discovery and is designed to replicate key features of the human immune system to overcome the limitations of competing antibody discovery technologies. AnaptysBio has also developed multiple therapeutic antibodies in partnership with Celgene and TESARO, including an anti-PD-1 antagonist antibody (TSR-042) and an anti-TIM-3 antagonist antibody (TSR-022), which are currently under clinical development with TESARO, and an undisclosed anti-inflammatory antibody currently in the clinic with Celgene.

Contact: Monique Allaire THRUST Investor Relations 617.895.9511 monique@thrustir.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Midea's Cooling Systems Take Center Stage at DCW ME

Updated Category News Views 64

AI Surge Demands Cooler Solutions Alright, who'd guess that data centers would feel the heat—literally—like a welder's furnace in Abu Dhabi? As AI demand burns hotter across the Middle East, data centers are sweating it out against 50°C-plus temperatures. We're talking about some serious pressure on traditional cooling methods that just can’t cut it anymore....

Continue Reading
Spruce Spins Adrenyx En Route to Nasdaq in 2027

Updated Category News Views 114

New Frontiers: Adrenyx Biosciences Takes Shape Well, here's a new chapter in biotech drama. Spruce Biosciences, a name you might have tangled with if you're into tickers like NASDAQ:SPRB, just carved out a niche with the birth of Adrenyx Biosciences. The play? A separate company eyeing the endocrinology space, setting its sights on tackling congenital adrenal hyperplasia...

Continue Reading
Thoughts Unleashed Arrives With a Personal American Voice

Updated Category News Views 114

A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...

Continue Reading
STORMER LAT Targets Sewer Crews' Costly Access Delays

Updated Category News Views 65

A buried cleanout can turn a simple sewer inspection into a scheduling circus. That unglamorous headache is exactly where FIBERSCOPE is aiming its new STORMER LAT Lateral Launch Camera System, announced November 17, 2026. This is not some flashy consumer gadget hunting for attention; it is field equipment built around a painfully ordinary municipal problem: crews often...

Continue Reading
Benicia's Bold Move to Streamline Permitting Pays Off

Updated Category News Views 147

Award-Winning Innovation from Benicia Benicia, California, shoots ahead of the pack by scooping up a highly coveted Helen Putnam Award for Excellence. Why? They chopped down bureaucracy like a lumberjack with a new ax by ushering in a digital revolution for their permitting process. Make no mistake, folks, this ain’t just a pat on the back—it's a blueprint for cities...

Continue Reading
Sola's 11-Step Push Makes Salon Ownership Less Blind

Updated Category News Views 141

A pristine studio does not pay rent by itself. That is the uncomfortable little truth sitting underneath Sola Salons’ new 11-step roadmap for beauty professionals considering salon-suite ownership. The company is telling stylists, estheticians, nail technicians, massage therapists, and other independent operators to treat the move from commission work to ownership like...

Continue Reading
SteriLance Aims for Smoother Pricks with NanoSense Move

Updated Category News Views 23

Revamping the Lancing Game Out there in Suzhou, SteriLance Medical is steering clear of just chasing meter accuracy—do enough folks even care about glorified electronics?—they're zeroing in on the needle part of the blood glucose test, the part that pricks your finger every damn day. Yep, this new initiative is inviting blood glucose monitoring (BGM) brands to embrace...

Continue Reading
Teen Adoption Campaign Makes Room for Mutual Growth

Updated Category News Views 8

A bicycle wobble and a ballet count carry more weight than they first appear to. The new Adoption from Foster Care public service ads put teens in the instructor's spot: a son helps his mother learn to ride a bike in Two Wheeler, while a daughter walks her father through ballet in Routine. It is a small creative reversal, but a smart one. Teen adoption is too often framed...

Continue Reading
Abacus Global Faces Scrutiny Over Accounting Practices

Updated Category News Views 149

Storm Clouds Gather over Abacus Global Management If it ain't one thing, it's another—at least that's what folks holding the bag with Abacus Global (ABX) are thinking right now. News of a pending investigation has dropped like a lead balloon, and the air is thick with scrutiny over their financial dealings. We're jawing about related-party transactions now under the...

Continue Reading
Exiger's CEO Honored for Military Support Excellence

Updated Category News Views 80

Recognizing Civilian and Military Leadership When you hear "recognition in the military sector," it isn't just a pat on the back. It's a whole parade of brass hats and high-flyers giving their nods. So, November 10th wasn't just any regular day—Brandon Daniels, CEO of Exiger, gets a shiny, prestigious Five-Star Award for his "extraordinary support" of our military...

Continue Reading

Top 5 Most Recently Viewed Articles

Embassy Bancorp, Inc. Reports Strong Financial Growth for Q2

Updated Category News Views 197

Embassy Bancorp, Inc. Financial Results Overview Embassy Bancorp, Inc. (OTCQX: EMYB) has recently released a comprehensive report highlighting its operations and financial achievements for the quarter ended June 30, 2025. The report outlines the ongoing stability and growth of the company, reinforcing its position in the competitive banking landscape. Key Financial...

Continue Reading
Unlocking New Features: Wijmo 2025 v2 by MESCIUS USA, Inc.

Updated Category News Views 200

Wijmo 2025 v2: A Leap Forward in Enterprise Software MESCIUS USA Inc. has officially launched Wijmo 2025 v2, marking the last major release for the year. This version not only promises cutting-edge features but also showcases their commitment to enhancing developer experiences across frameworks. Included in this release is robust support for Angular 20 and Nuxt.js 4,...

Continue Reading
Titan Investors Teams with Corridor for Global Expansion

Updated Category News Views 42

Titan Investors Takes a Bold Leap Forward Alright folks, here's a change in the wind that's got my attention. Titan Investors, a heavyweight in the investment event business, has just locked arms with Corridor Capital. Yeah, we're talking about a private equity firm with a knack for boosting the game of middle-market business services across North America. If you're...

Continue Reading
Examining the Implications of a 'Shadow' Fed Chair Role

Updated Category News Views 166

The Emerging Concept of a ‘Shadow’ Fed Chair There has been growing tension surrounding Chairman Powell, particularly with rising frustration from Donald Trump. Reports indicate that Trump may expedite his decision on Powell's successor, creating anticipation for a so-called 'shadow Fed Chair' who would shape economic opinions until Powell's term concludes in 2026....

Continue Reading
U.S. Postal Service Reports Growth and Financial Improvements

Updated Category News Views 294

U.S. Postal Service Financial Results Overview The U.S. Postal Service has recently shared its financial outcomes for the first quarter of fiscal year 2025, revealing impressive growth metrics that mark a significant turnaround from previous years. Controllable income has doubled to $968 million, a substantial increase from $472 million during the same period last year,...

Continue Reading